Deciphera Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DCPH research report →
About the company
Deciphera Pharmaceuticals, Inc. is a biopharmaceutical firm focused on developing innovative therapies to significantly improve outcomes for cancer patients. Their core strategy involves tackling the mechanisms of drug resistance that often limit the effectiveness and longevity of current cancer treatments, serving markets both domestically and internationally.
- CEO
- Steven L. Hoerter
- IPO
- 2017
- Employees
- 355
- HQ
- Waltham, MA, US
Price Chart
- Market Cap
- $2.21B
- P/E
- -11.17
- P/S
- 13.55
- P/B
- 6.20
- EV/EBITDA
- -10.32
- Div Yield
- 0.00%
- Gross Margin
- 97.72%
- Op Margin
- -129.14%
- Net Margin
- -119.34%
- ROE
- -56.29%
- ROIC
- -55.99%
- Revenue
- $163.36M · 21.87%
- Net Income
- $-194,942,000 · -8.95%
- EPS
- $-2.29 · 3.38%
- Op Income
- $-210,958,000
- FCF YoY
- 4.05%
- 52W High
- $25.61
- 52W Low
- $9.90
- 50D MA
- $21.07
- 200D MA
- $15.75
- Beta
- 0.18
- Avg Volume
- 1.86M
Get TickerSpark's AI analysis on DCPH
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 22, 24 | Brightstar Associates LLC | other | 48,136 |
| Apr 22, 24 | Brightstar Associates LLC | other | 48,136 |
| Feb 15, 24 | Sherman Matthew L | other | 17,275 |
| Feb 16, 24 | Sherman Matthew L | sell | 2,615 |
| Feb 15, 24 | Sherman Matthew L | other | 69,100 |
| Feb 15, 24 | Kelly Thomas Patrick | other | 17,275 |
| Feb 16, 24 | Kelly Thomas Patrick | sell | 3,010 |
| Feb 15, 24 | Kelly Thomas Patrick | other | 69,100 |
| Feb 15, 24 | Pitman Jama | other | 10,000 |
| Feb 16, 24 | Pitman Jama | sell | 2,267 |
Our DCPH coverage
Recent articles, reports, and earnings notes.
No research on DCPH yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate DCPH report →Similar companies
Peers in the same neighborhood.